New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - risperidone 1mg;   - film coated tablet - 1 mg - active: risperidone 1mg   excipient: colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc   sodium laurilsulfate - treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness),and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - risperidone - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - risperidone - oral tablet - 1mg

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - risperidone 1mg - film coated tablet - 1 mg - active: risperidone 1mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose opadry white oy-58900 purified talc sodium laurilsulfate starch - risperidone tablets are indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. · risperidone tablets also alleviate affective symptoms (such as depression, guiltfeelings, anxiety) associated with schizophrenia.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 2 mg - adults risperidone (risperidone) is indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)]. adolescents risperidone is indicated for the treatment of schizophrenia in adolescents aged 13–17 years [see clinical studies (14.1)]. monotherapy adults and pediatrics risperidone is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults and in children and adolescents aged 10-17 years [see clinical studies (14.2)]. combination therapy adults the combination of risperidone with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder [see clinical studies (14.3)]. pediatrics risperidone is indicated for the treatment of irritability associated with autistic disorder in children and adolescents aged 5–16 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods [see clinic

Canada - English - Health Canada

marcan pharmaceuticals inc - risperidone - tablet - 1mg - risperidone 1mg - atypical antipsychotics

Canada - English - Health Canada

angita pharma inc. - risperidone - tablet - 1mg - risperidone 1mg - atypical antipsychotics

United States - English - NLM (National Library of Medicine)

cardinal health - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - risperidone is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing

United States - English - NLM (National Library of Medicine)

citron pharma llc - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - risperidone tablets are indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] .  adjunctive therapy risperidone tablets adjunctive therapy with lithium or valproate are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone tablets are indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate se

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - risperidone - orodispersible tablet - 1mg